Using Patient-Derived 3D Cell Culture Models for Semi-Automated Drug Screening
23 Oct 2017

In this webinar, you will learn how comprehensive patient-derived 3D cell culture models can be integrated into the pre-clinical development of novel anti-cancer compounds. The benefits of using these cell cultures instead of adherent 2D cell lines will be explained and current limitations will be illustrated. The webinar will explore a prototypic workflow and explain a semi-automated setup for high-throughput screening (HTS). In the second part of the webinar, the use of patient-derived cell culture models in personalized oncology will be discussed and practical examples will be shown.

Dr. Christian Regenbrecht, Founder and CEO, Cellular Phenomics & Oncology (CPO), will discuss:

  • How patient-derived 3D cell culture models can be integrated into the pre-clinical development of novel anti-cancer compounds

  • The advantages of using 3D cell culture models over adherent 2D cell lines

  • Prototypic workflows and semi-automated setup for HTS

  • Examples of the use of patient-derived cell culture models in personalized oncology

Who should attend?

Scientists from pharma, biotech and academia who work in the field of pre-clinical drug development. Decision makers who want to explore opportunities to reduce the use of animal models. Oncologists who want to be informed about how this will transform future patient care.

Molecular Devices®